Copiktra (duvelisib): Drug Safety Communication - FDA Warns about Possible Increased Risk of Death and Serious Side Effects

Nathan E Botts 0506
Categories: Medical Devices
FDA is warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer.

Link to original article

Share
Print
Please login or register to post comments.